

AMBEY LABORATORIES LIMITED

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: accountho@ambeylab.com

www.ambeylab.com

Date: 14.11.2025

To,

The Head – Listing & Compliance
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (E) Mumbai – 400 051

Symbol: AMBEY
ISIN : INE0M3I01029

Sub: Outcome of the meeting of the Board of Directors held on November 14, 2025

Ref: Regulation 30 (read with Part A of Schedule III) and Regulation 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), this is to inform you that the Board of Directors of the Company, at its meeting held today, i.e., on Friday, November 14, 2025, has considered and approved the following items:

Unaudited Financial Results for the half year ended on September 30, 2025,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. A copy of Unaudited Standalone Financial Results of the Company for the half year ended September 30, 2025;
2. A copy of Unaudited Consolidated Financial Results of the Company for the half year ended September 30, 2025;
3. The Limited Review Reports of the Statutory Auditors of the Company on the aforesaid Unaudited Standalone & Consolidated Financial Results;
4. Statement of Assets & Liabilities (Standalone & Consolidated) of the Company for the half year ended September 30, 2025;
5. Cash Flow Statement (Standalone & Consolidated)of the Company for the half year ended September 30, 2025;
6. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc. “Annexure-A”;

AMBEY LABORATORIES LIMITED

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: accountho@ambeylab.com

www.ambeylab.com

7. Disclosure of Related Party Transactions of the Company for the half year ended September 30, 2025;

Statement of Impact of Audit Qualifications- Not Applicable.

The Board Meeting commenced at 6:45 PM and concluded at 7:30 PM.

Kindly take the above information on record and oblige.

Thanking you,

For: AMBEY LABORATORIES LIMITED

Himanshu Kukreja
Company Secretary
Membership No: A64853

Enc: aa

AMBEY LABORATORIES LIMITED

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: accountho@ambeylab.com

www.ambeylab.com

Annexure-A

Statement of Deviation/Variation in the utilization of funds raised

Amount in Lakhs

Name of listed entity	AMBEY LABORATORIES LIMITED
Mode of Fundraising	Preferential Issue
Date of Raising Funds	14 th August, 2025 & 19 th August, 2025
Amount Raised	3,12,49,996.5 & 9,37,50,001
Report filed for the Half Year ended	30th September, 2025
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If Yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation/Variation	Not Applicable
Comments of the Audit Committee after review	Not Applicable
Comments of the auditor, if any	Not Applicable

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e., letter of offer, etc

AMBEY LABORATORIES LIMITED

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: accountho@ambeylab.com

www.ambeylab.com

Original Object	Modified Objective if any	Original Allocation	Modified allocation, if any	Funds Utilized	Amount of Deviation/Variation for the according quarter to applicable object	Remark if any
For purchasing land, Building, plant and machinery & General Corporate purpose	Not Applicable	1,24,999,997.5	Not Applicable	1,24,999,997.5	Not Applicable	None
Total		1,24,999,997.5		1,24,999,997.5		

Kindly take the above information for your records.

For: AMBEY LABORATORIES LIMITED

Himanshu Kukreja
Company Secretary
Membership No: A64853



F.R.N. 022743N

KAPISH JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the half year ended 30 September 2025 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Ambey Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Ambey Laboratories Limited** ("the Company") for the half year ended 30 September 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation")) as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.




5. During the half year ended on 30 September 2025, the Company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilized for the purposes detailed in the table below.

Rs. In Lakhs				
Object of issue	Amount received (25% of total value)	Amount utilized till September 30, 2025	Amount unutilized till September 30, 2025	Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	1,250.00	1,250.00	-	N/A

For **KAPISH JAIN & ASSOCIATES**
Chartered Accountants
Firm Registration No. 022743N



CA Kapish Jain
Partner
M. No.: 514162
UDIN: 25514162BMJVGE8958
Place: New Delhi
Date: 14 November 2025

AMBEY LABORATORIES LIMITED Regd. Office : Ground Floor, Property No. 555 Taria Mohalla, Ghitorni, South West Delhi, Delhi, India, 110030 Corp. Office : B18/9, Dlf Phase - I Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002 CIN: L74899DL1985PLC020490, Email: cs@ambeylab.com				
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025				
Sl. No	Particulars	Half year ended		Rs. In Lakhs
		30.09.2025	31.03.2025	Year ended
		(Unaudited)	(Audited)	31.03.2025
1	Income			
	a) Revenue from operations	6,817.59	6,361.76	13,126.99
	b) Other income	13.37	114.16	191.61
	Total Income	6,830.96	6,475.92	13,318.60
2	Expenses			
	a) Cost of material consumed	6,176.51	5,764.22	11,883.06
	b) Changes in inventories of work-in-progress, finished goods	(226.46)	8.18	(183.33)
	c) Employee benefits expense	77.01	102.54	174.99
	d) Finance costs	192.11	171.12	291.16
	e) Depreciation and amortisation expense	110.09	75.80	254.30
	f) Other expenses	201.13	111.42	294.59
	Total expenses	6,530.39	6,233.28	12,714.77
3	Profit/(loss) before exceptional item & tax (1-2)	300.57	242.64	603.83
4	Exceptional Items	-	-	-
5	Profit/(loss) before tax (3-4)	300.57	242.64	603.84
6	Tax expense	56.52	57.66	113.95
	Deferred tax charge/ (benefit)	38.40	60.93	125.56
	MAT credit entitlement	(56.52)	(57.66)	(113.95)
	Tax expense	38.40	60.93	125.56
7	Net Profit/(Loss) after tax (5-6)	262.17	181.71	478.27
8	Paid-up Equity Share Capital (Face value of Rs.10/- each)	2,494.68	2,494.68	2,494.68
9	Reserves (excluding revaluation reserve)			4,090.35
10	Earnings per equity share			
	(Nominal value per share Rs. 10) (not annualised, except year end)			
	Basic earnings per share (in ₹)	1.05	0.78	2.06
	Diluted earnings per share (in ₹)	1.05	0.78	2.06

Notes:-

- 1 The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 November 2025.
- 2 The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.

For and Behalf of Board of
Ambey Laboratories Limited


Archit Gupta
Archit Gupta
Whole Time Director
DIN 00378409



Date: 14 November 2025
Place: Gurugram

5	STANDALONE STATEMENT OF ASSETS & LIABILITIES			
	Particulars	Standalone		
		As at 30.09.2025	As at 31.03.2025	
	EQUITY AND LIABILITIES			
1	Shareholders' funds			
	a) Share capital			
	b) Reserves and surplus	2,494.68	2,494.68	
	c) Money Received Against share warrant	5,402.51	5,140.35	
	Total Equity	1,250.03	-	
		9,147.22	7,635.03	
2	Share Application Money Pending Allotment			
		-	-	
3	Liabilities			
	Non-current liabilities			
	a) Long-Term Borrowings			
	b) Deferred tax liabilities	1,893.41	1,074.82	
	c) Other long-term liabilities	-	-	
	d) Long-term provisions	-	-	
	Total non-current liabilities	53.59	53.59	
	Current liabilities	1,947.00	1,128.41	
	a) Short-Term Borrowings			
	b) Trade payables	2,108.78	3,009.48	
	(i) Total outstanding dues of micro enterprises and small enterprises; and			
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	69.53	94.49	
	c) Other current liabilities	468.95	568.58	
	d) Short-term provisions	155.41	192.75	
	Total current liabilities	109.77	92.47	
		2,912.44	3,957.77	
	Total equity and liabilities			
	Assets	14,006.66	12,721.21	
1	Non-current assets			
	a) Property, plant and equipment			
	(i) Property, plant and equipment			
	(ii) Intangible assets	2,150.87	2,253.89	
	(iii) Capital work-in-progress	50.81	57.70	
	b) Non-current investments	1,717.75	1,566.42	
	c) Deferred tax assets (Net)	10.00	-	
	d) Long-term loans and advances	103.65	142.06	
	e) Other non-current assets	411.22	47.93	
	Total non-current assets	-	-	
		4,444.30	4,068.00	
2	Current assets			
	a) Current investment			
	b) Inventories			
	c) Trade receivables	3,061.24	2,991.32	
	d) Cash and bank balances	4,997.68	4,043.19	
	e) Short-term loans and advances	164.62	176.30	
	f) Other current assets	1,283.11	1,354.95	
	Total current assets	55.71	87.45	
		9,552.36	8,653.21	
	Total assets	14,006.66	12,721.21	

For and Behalf of Board of
Ambeey Laboratories Limited



Archit Gupta
Whole Time Director
DIN 00378409

Date: 14 November 2025
Place: Gurugram

For and Behalf of Board of
Ambey Laboratories Limited

Archit Gupta
Whole Time Director
DIN 00378409

Date: 14 November 2025
Place: Gurugram



STANDALONE STATEMENT OF CASH FLOWS

	Rt. In Lakhs	
	For the half year ended	
	30.09.2025	30.09.2024
A. Cash flow from operating activities		
Profit/(loss) before tax		
Adjustments for :		
Depreciation and amortisation expense	300.56	361.19
Net (profit)/ loss on disposal of property, plant and equipment	110.09	120.04
Interest expense and finance cost	-	(1.22)
Unrealised foreign currency (gain)/loss	192.11	178.50
Interest income	-	(0.61)
	(4.29)	(12.59)
Changes in assets and liabilities		
(Increase) / Decrease in inventories	598.47	645.31
(Increase) / Decrease in trade receivables	(69.92)	(649.89)
(Increase) / Decrease in long term loans and advances	(954.49)	(3,574.81)
(Increase) / Decrease in short term loans and advances	(363.28)	(422.90)
(Increase) / Decrease in other assets	87.75	(93.20)
Increase / (decrease) in trade payables	31.75	(98.67)
Increase / (decrease) in short term provisions	(124.59)	1,192.96
Increase / (decrease) in long term provisions	-	52.41
Increase / (decrease) in other liabilities	-	14.37
Cash generated from operating activities	(37.33)	169.43
Taxes paid (net of refunds)	(831.64)	(2,764.99)
Net cash generated from operating activities	1.37	(33.39)
	(830.27)	(2,798.38)
B. Cash Flow from Investing Activities		
(Purchase) Sale of Fixed Assets		
Investment in subsidiary companies	(151.51)	(496.89)
Investment in Fixed Deposit	(10.00)	-
Interest received	1.79	(368.84)
Net cash generated from/(used in) investing activities	4.29	12.59
	(155.43)	(853.14)
C. Cash flows from financing activities		
Interest & Finance Cost		
Proceeds from issues of equity shares	(192.11)	(178.50)
Proceeds of long term borrowings	-	4,005.44
(Repayments) / proceeds of short term borrowings	818.59	(249.38)
Proceeds from issues of share warrants	(900.70)	84.18
Net cash generated from/(used in) financing activities	1,250.03	-
	975.81	3,661.74
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(9.89)	10.22
Cash and cash equivalents at the beginning of year	72.76	36.50
Cash and cash equivalents at the end of year	62.87	46.72

The above statement of cash flow has been prepared under the 'Indirect Method'.

- 7 During the FY 2025-26, the Company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date. The 25% money received against these warrants has been utilised for the purposes detailed in the table below.

Object of issue	Amount received	Amount utilized till 30 September 2025	Amount unutilized till 30 September 2025	Deviation (if any)
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances made through the Subsidiary to facilitate future expansion and development plans.	1250.00	1250.00	-	-
Total	1250.00	1250.00	-	-

- 8 The standalone financial results include the results for the half year ended 31 March 2025, being the balancing figures between the audited figures in respect of the full financial year ended 31 March 2025 and the figures for the half year ended 30 September 2024.
- 9 The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

For and Behalf of Board of
Ambeey Laboratories Limited

Archit Gupta
Whole Time Director
DIN 00378409

Date: 14 November 2025
Place: Gurugram





F.R.N. 022743N

KAPISH JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

Independent Auditor's Review Report on Consolidated Un-audited Financial Results for the six months ended 30 September 2025 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Ambey Laboratories Limited**

1. We have reviewed the accompanying Statement of Consolidated Un-audited Financial Results of **Ambey Laboratories Limited** ("the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") for the six months ended 30 September 2025 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related unaudited interim financial information which has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. The Statement includes the results of following entity:

S. No.	Name of the entity	Relation
1	Dhansa Green Energy Private Limited (w.e.f. August 14, 2025)	Subsidiary Company

5. The holding company acquired 100% stake in Dhansa Green Energy Private Limited ("the subsidiary company"), with effect from 14th August 2025. As a result, the consolidated figures for the six-months ended 30 September 2025, include subsidiary's financials from that date onward. Consequently, comparative figures for the six-months ended 30 September 2024, and for the six months and year ended March 2025 are not presented in these results, as subsidiary companies were not part of the group during those periods.
6. The consolidated financial results include the financial results of subsidiary, whose financial statements/financial information reflect total assets of Rs. 2.81 lacs & net assets of Rs. 0.15 lacs as at 30 September 2025 and total revenue of Rs. nil lacs & total net profit / (loss) after tax of Rs. (0.15) lacs for the six months ended 30 September 2025 and cashflow inflow (net) of Rs. 73.76 lacs, as considered in the unaudited consolidated financial results which have been reviewed by their respective independent auditors. The independent auditor's reports on financial statements/ financial information of these entities have been furnished to us by the management.

Our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our conclusion on the consolidated unaudited financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

7. Based on our review conducted as stated above, nothing has come to our attention that that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.




8. During the FY 2025-26, the holding company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilized for the purposes detailed in the table below.

Rs. In Lakhs				
Object of issue	Amount received (25% of total value)	Amount utilized till September 30, 2025	Amount unutilized till September 30, 2025	Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	1,250	1,250	-	N/A

For **KAPISH JAIN & ASSOCIATES**
Chartered Accountants
Firm Registration No. 022743N


CA Kapish Jain
Partner
M. No.: 514162
UDIN: 25514162BMJVG2182



Place: New Delhi
Date: 14 November 2025

AMBEY LABORATORIES LIMITED					
Regd. Office : Ground Floor,Property No.555 Tarla Mohalla,Ghikorni, South West Delhi, Delhi, India, 110030					
Corp. Office : B18/9, Dlf Phase -I Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002					
CIN: L74899DL1985PLC020490, Email:cs@ambeylab.com					
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS					
FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025					
					Rs. In Lakhs
Sl. No	Particulars	Half year ended			Year ended
		30.09.2025	31.03.2025	30.09.2024	31.03.2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	6,817.59	-	-	-
	b) Other income	13.37	-	-	-
	Total Income	6,830.96	-	-	-
2	Expenses				
	a) Cost of material consumed	6,176.51	-	-	-
	b) Changes in inventories of work-in-progress, finished goods	(226.46)	-	-	-
	c) Employee benefits expense	77.01	-	-	-
	d) Finance costs	192.11	-	-	-
	e) Depreciation and amortisation expense	110.09	-	-	-
	f) Other expenses	201.28	-	-	-
	Total expenses	6,530.54	-	-	-
3	Profit/(loss) before exceptional item & tax (1-2)	300.42	-	-	-
4	Exceptional Items	-	-	-	-
5	Profit/(loss) before tax (3-4)	300.42	-	-	-
6	Tax expense	56.52	-	-	-
	Deferred tax charge/ (benefit)	38.40	-	-	-
	MAT credit entitlement	(56.52)	-	-	-
	Tax expense	38.40	-	-	-
7	Net Profit/(Loss) after tax (5-6)	262.02	-	-	-
8	Paid-up Equity Share Capital (Face value of Rs.10/- each)	2,494.68	-	-	-
9	Reserves (excluding revaluation reserve)				
10	Earnings per equity share				
	[Nominal value per share Rs. 10] (not annualised, except year end)				
	Basic earnings per share (in ₹)	1.05	-	-	-
	Diluted earnings per share (in ₹)	1.05	-	-	-

Notes:-

1

The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 November 2025.

2

The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3

The Holding Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Holding Company has a single reportable segment as per the Accounting Standard - 17.

For and Behalf of Board of
Ambey Laboratories Limited

Archit Gupta
Whole Time Director
DIN 00378409

AMBEY LABORATORIES LIMITED

Date: 14 November 2025
Place: Gurugram

5	CONSOLIDATED STATEMENT OF ASSETS & LIABILITIES		
	Particulars	Consolidated	
		As at 30.09.2025	As at 31.03.2025
	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a) Share capital	2,494.68	-
	b) Reserves and surplus	5,402.36	-
	c) Money Received Against share warrant	1,250.03	-
	Total Equity	9,147.07	-
2	Share Application Money Pending Allotment	-	-
3	Liabilities		
	Non-current liabilities		
	a) Long-Term Borrowings	1,895.02	-
	b) Deferred tax liabilities	-	-
	c) Other long-term liabilities	-	-
	d) Long-term provisions	53.59	-
	Total non-current liabilities	1,948.61	-
	Current liabilities		
	a) Short-Term Borrowings	2,108.78	-
	b) Trade payables		
	(i) Total outstanding dues of micro enterprises and small enterprises; and	69.53	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	468.95	-
	c) Other current liabilities	156.76	-
	d) Short-term provisions	109.77	-
	Total current liabilities	2,913.79	-
	Total equity and liabilities	14,009.47	-
	Assets		
1	Non-current assets		
	a) Property, plant and equipment		
	(i) Property, plant and equipment	2,150.87	-
	(ii) Intangible assets	50.81	-
	(iii) Capital work-in-progress	1,721.76	-
	b) Non-current investments	-	-
	c) Deferred tax assets (Net)	103.65	-
	d) Long-term loans and advances	119.02	-
	e) Other non-current assets	-	-
	Total non-current assets	4,146.11	-
2	Current assets		
	a) Current investment	-	-
	b) Inventories	3,061.23	-
	c) Trade receivables	4,997.68	-
	d) Cash and bank balances	165.62	-
	e) Short-term loans and advances	1,583.12	-
	f) Other current assets	55.71	-
	Total current assets	9,863.36	-
	Total assets	14,009.47	-

For and Behalf of Board of
Ambey Laboratories Limited

Archit Gupta

Archit Gupta
Whole Time Director
DIN 00378409

Date: 14 November 2025
Place: Gurugram



6	CONSOLIDATED STATEMENT OF CASH FLOWS	Rs. In Lakhs	
		For the half year ended	
		30.09.2025	30.09.2024
A.	Cash flow from operating activities		
	Profit/(loss) before tax	300.41	-
	Adjustments for :		
	Depreciation and amortisation expense	110.09	-
	Interest expense and finance cost	192.11	-
	Interest income	(4.29)	-
	Consolidated adjustment	7,492.97	-
		8,091.29	-
	Changes in assets and liabilities		
	(Increase) / Decrease in inventories	(3,061.23)	-
	(Increase) / Decrease in trade receivables	(4,997.68)	-
	(Increase) / Decrease in long term loans and advances	(119.02)	-
	(Increase) / Decrease in short term loans and advances	(1,154.40)	-
	(Increase) / Decrease in other assets	(55.71)	-
	Increase / (decrease) in trade payables	538.50	-
	Increase / (decrease) in short term provisions	34.54	-
	Increase / (decrease) in long term provisions	53.59	-
	Increase / (decrease) in other liabilities	156.76	-
	Cash generated from operating activities	(513.36)	-
	Taxes paid (net of refunds)	(353.48)	-
	Net cash generated from operating activities	(866.84)	-
B.	Cash Flow from Investing Activities		
	(Purchase) Sale of Fixed Assets	(4,033.54)	-
	(Purchase) Sale of Current Investment	-	-
	Investment in Fixed Deposit	(101.75)	-
	Interest received	4.29	-
	Net cash generated from/(used in) Investing activities	(4,131.00)	-
C.	Cash flows from financing activities		
	Interest & Finance Cost	(192.11)	-
	Proceeds from issues of equity shares	-	-
	Proceeds of long term borrowings	1,895.02	-
	(Repayments) of long term borrowings	-	-
	(Repayments) / proceeds of short term borrowings	2,108.77	-
	Proceeds from issues of share warrants	1,250.03	-
	Net cash generated from/(used in) financing activities	5,061.71	-
	Net increase/(decrease) in cash and cash equivalents (A+B+C)	63.87	-
	Cash and cash equivalents at the beginning of year	-	-
	Cash and cash equivalents at the end of year	63.87	-

The above statement of cash flow has been prepared under the 'Indirect Method'.

- 7 During the FY 2025-26, the holding company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilised for the purposes detailed in the table below.

Object of issue	Amount received	Amount utilized till 30 September 2025	Amount unutilized till 30 September 2025	Deviation (If any)
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances made through the Subsidiary to facilitate future expansion and development plans.	1250.00	1250.00	-	-
Total	1250.00	1250.00	-	-

- 8 The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

For and Behalf of Board of
Ambeey Laboratories Limited

Archit Gupta
Whole Time Director
DIN 00378409

Date: 14 November 2025
Place: Gurugram



Related Party Transactions for the Half Year period ended on 30.09.2025

Amount in Lakhs

[illegible][illegible]